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ABSTRACT
The introduction of vaccination against SARS-CoV-2 infection was a welcome and significant
event in the COVID-19 pandemic. While vaccine administration was for the most part
successful, it did come with the emergence of a novel condition, Vaccine-Induced Thrombotic
Thrombocytopenia (VITT). This condition presents after the administration of adenoviral
vector-based vaccines against COVID-19, causing thrombocytopenia and thrombosis in
affected individuals. There have been ten suspected cases of VITT in Ireland reported up to
March 2022. While its mechanism is not fully understood, the condition is characterised by the
presence of Platelet Factor 4 (PF4) antibodies. There are several laboratory indicators which
may suggest that a patient has developed VITT, but confirmatory diagnosis requires anti-PF4
ELISA and PF4 Activation Assays. Thrombocytopenia often precedes thrombosis in VITT, so
early treatment can aid in preventing the more serious implications of the condition from
developing. Early recognition and clear guidelines for diagnosis are imperative in the treatment
of VITT.
INTRODUCTION
Vaccine-Induced Thrombotic Thrombocytopenia (VITT) is a novel condition which has been
recently identified following the administration of vaccines against the pandemic disease
COVID-19. In Europe, four COVID-19 vaccines have been approved for use (EMA, 2021).
The mechanism by which these vaccines induce immunity has been well documented. Two
mRNA vaccines are in use, the Pfizer/BioNTech and Moderna vaccines. These vaccines work
through the administration of mRNA which encodes the production of an antigen. The vaccine
mRNA is taken up by cells, which are then prompted to produce the antigen, which in this case
is the spike glycoprotein of SARS-CoV-2. The immune system will then launch an immune
response against the foreign antigen which has been produced, creating antibodies which attack
the spike glycoprotein. This means that on re-infection by SARS-CoV-2, the immune system
will quickly recognise and mount an immune response against the spike glycoprotein (Chung,
Thone and Kwon, 2021). The spike glycoprotein plays an important role in the entry of
SARSCoV-2 into cells, so antibodies against this antigen will block or slow the entry of the
virus into the cells (Ortiz-Prado et al., 2020).
The other two vaccines approved for use are the AstraZeneca and Janssen vaccines, which are
both adenoviral vector-based. Viral vector vaccines work by replacing a gene responsible for
replication with a gene which encodes the required antigen in the viral vector. When
administered, this will cause cells to produce the antigen of interest, in this case the spike
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glycoprotein of SARS-CoV-2, while also preventing the virus itself from replicating
(McGonagle et al., 2021). After the production of the spike glycoprotein, the adenoviral vector
vaccines work in the same way as the mRNA-based vaccines to promote the immune system
to mount a response against the spike glycoprotein. Development of VITT follows the
administration of adenoviral-vector vaccines against SARS-CoV-2, although very rare cases of
thrombosis following mRNA vaccine administration have also been reported (Elalamy et al.,
2021).
VITT has been reported among recipients of the Oxford AstraZeneca ChAdOx1 nCov19 (now
Vaxzevria) and Janssen Ad26.COV2.S vaccines (Greinacher, Thiele et al., 2021). VITT is
uncommon and affects a low number of vaccine recipients. One of the highest incidence rates
was reported in Norway, where VITT developed in 1:22,000 individuals who received an
adenoviral vector vaccination. If left untreated the condition can have serious implications and
has in some cases caused fatality (Favaloro, 2021). For such reasons, early detection and rapid
treatment is of vital importance.
Symptoms of VITT have been seen to develop 4-42 days post vaccination and can include
headache, abdominal or back pain, focal changes, petechiae, easy bruising or bleeding, nausea
or vomiting and shortness of breath (Kotal et al., 2021). Laboratory indicators suggestive of
VITT include a low platelet count, prolonged prothrombin time (PT) and activated partial
thromboplastin time (APTT), and elevated d-dimer levels (Favaloro, 2021). If such markers are
present in a patient suspected of having VITT, further testing is warranted to confirm the
diagnosis.
VITT is characterised by the presence of Platelet Factor 4 (PF4) antibodies in individuals who
have recently received a vaccine. The presentation and mechanism of VITT is thought to be
closely like that of heparin-induced thrombotic thrombocytopenia (HIT), another condition
which is characterised by the presence of anti-PF4 antibodies (Klok et al., 2021). PF4 Anti IgG
ELISA testing and Platelet Factor 4 Induced Platelet Activation Assays (PIPA) can be used to
confirm the presence of PF4 antibodies, which will confirm the diagnosis of VITT (Lavin et
al., 2021). Since this is a newly emerging condition, little is known about what proportion of
vaccine recipients develop VITT or how the vaccine triggers the thrombotic thrombocytopenic
response seen in VITT. This review assimilates and analyses what has been reported about
VITT and discusses laboratory investigation of the condition and current treatment so far.
REPORTED INCIDENCE OF VITT
Variation in the incidence of VITT has been reported between different countries and different
age groups. In the UK, the incidence is reported as being 1:100,000 for patients over the age of
50, and 1:50,000 for patients under the age of 50 (Pavord et al., 2021). Norway has reported a
much higher incidence rate, with 1:22,000 of all individuals vaccinated developing VITT
(Wiedmann et al., 2021). It has been suggested that VITT is less prevalent in Asian populations,
as is the case with HIT. In South Korea after the administration of 7.9 million doses of
adenoviral vector-based vaccines there had only been ten cases of VITT, giving an incidence
of 1:790,000, much lower than rates reported in Europe (Kim et al., 2021). Although literature
on the incidence of VITT in Ireland has so far been minimal, it has been reported that there
have been ten suspected cases of VITT in the country to date (March 2022) with no associated
deaths. Nine of the cases occurred following vaccination with the AstraZeneca vaccine, and
one case following the Janssen vaccine (Swan et al., 2021).
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The first publications of VITT reported fatality rates was of 55-60% (Klok et al., 2021). A more
recent publication in the UK reported a fatality rate of 23%, which is still very significant
(Pavord et al., 2021). This difference in reported rates may be due to the underreporting of
cases when the condition was first described. Most cases where VITT has resulted in fatality
have been cases where extensive thrombosis has been present (Swan et al., 2021). The highest
mortality rate is associated with cases where the platelet count is below 30x109/L and
intracranial haemorrhage is reported (Pavord et al., 2021).
It has been shown that 54% of individuals affected by VITT are female (Pavord et al., 2021).
There appears to be a higher risk for younger age groups, with 85% of VITT patients being
under 60 years of age (Klok et al., 2021). Following the emergence of VITT, many countries
including Ireland, the UK, Germany, and Austria stopped the administration of the AstraZeneca
vaccine to younger age groups (Elalamy et al., 2021). The majority of VITT cases occur after
the first dose of a two-dose vaccine, and it has been recommended that any patients who
develop VITT after their first dose should receive an mRNA vaccine for their second dose
(Klok et al., 2021).
CLINICAL PRESENTATION AND GUIDELINES FOR DIAGNOSIS OF VITT
A wide range of symptoms have been reported to be associated with VITT, with the most
common including headache, nausea, visual disturbances, easy bruising, petechiae and acute
pain (Elalamy et al., 2021). On laboratory investigation, thrombocytopenia and elevated
Ddimer levels are common. Coagulation tests such as the prothrombin time (PT) and activated
partial thromboplastin time (aPTT) may be prolonged, and hypofibrinogenemia has also been
noted in numerous cases (Lavin et al., 2021). VITT is associated with thrombosis at unusual
sites, such as cerebral venous sinus thrombosis (CVST), splenic venous thrombosis (SVT) and
ophthalmic vein thrombosis (McDonnell et al., 2021), as well as more common presentations
of thrombosis such as deep-vein thrombosis (DVT) and pulmonary embolism (PE). Venous
thrombosis is also commonly present at multiple sites in VITT patients (Kotal et al., 2021).
Different publications have reported different time ranges for when the symptoms of VITT can
appear, with the widest range being 4 – 42 days post vaccination. VITT is an immune response
so any adverse reactions to a vaccination seen before 4 - 5 days post vaccination are not because
of VITT (Kotal et al., 2021).
When VITT was first recognised, the varied clinical presentation possible in VITT was not
fully appreciated. It was thought that thrombosis, thrombocytopenia, and elevated D-dimer
levels were present in all cases, and if a patient presented lacking one of these criteria VITT
was not suspected (Klok et al., 2021). One report detailed a case where a patient presented to
a hospital with headache, visual disturbance, nausea, thrombocytopenia, and elevated D-dimer
levels. Investigation found that there were no signs of thrombosis, so VITT was not suspected,
and the patient was discharged. The patient subsequently re-presented three days later with
worsening symptoms and the diagnosis of VITT was confirmed (Lavin et al., 2021). This delay
in the recognition of VITT can have a significant effect on patient outcome, so it is important
to highlight that not all cases will present with all classical signs of VITT.
One factor which may influence why there appears to be a delay between when a patient with
VITT first presents and when the diagnosis of VITT is confirmed is the discrepancy between
diagnostic guidelines which have been published since the condition emerged. One report used
four different sets of guidelines, published by the Society for Thrombosis and Haemostasias
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Research in Germany (GTH), UK Expert Haematology Panel (UK EHP), Thrombosis Canada
and International Society on Thrombosis and Haemostasis (ISTH), to evaluate case studies of
confirmed VITT cases (Lavin et al., 2021). The findings were that there was inconsistency in
what were considered diagnostic indicators between the different sets of guidelines. This
ambiguity in the recommendations for the diagnosis of VITT is a plausible reason as to why
there may have been a delay in recognising the signs of VITT when a patient first presented.
Since the identification of VITT some organisations including the UK EHP have updated their
guidelines for diagnosis (Pavord et al., 2021), there is now greater consistency between the
guidelines available.
Recent publications have suggested defining a new condition, ‘pre-VITT’. This condition was
suggested on the basis that patients with VITT can present with elevated D-dimer levels,
thrombocytopenia and anti-PF4 antibodies before they develop thrombosis (Salih et al., 2021;
Makris and Pavord, 2022). Recognition of this condition would allow such patients to be
identified and treated quickly, reducing the chance that they will develop thrombosis. In such
cases where ‘pre-VITT’ is present, it is important that the condition is recognised and not
mistaken for other thrombocytopenic conditions such as thrombotic thrombocytopenic purpura,
immune thrombocytopenic purpura, or catastrophic antiphospholipid syndrome (Makris and
Pavord, 2022). Given that SARS-CoV-2 infection can also cause thrombosis, current COVID19 disease should also be ruled out in a patient presenting with symptoms suggestive of VITT.
It should also be determined whether the patient has recently received heparin treatment so as
not to mistake the condition for HIT (Elalamy et al., 2021).
RELATIONSHIP BETWEEN COVID-19 DISEASE AND THROMBOSIS
Infection with SARS-CoV-2 has been associated with several cardiovascular complications,
including thrombosis. Thrombosis commonly occurs in patients who develop severe COVID19
disease (Zhang et al., 2020). Some research has investigated whether there could be a shared
cause for the thrombosis seen in COVID-19 and in VITT, due to the fact that both involve the
expression of the spike protein of SARS-CoV-2 (McGonagle et al., 2021). In COVID-19
disease, viral RNA is the main cause of thrombosis although research has shown that the spike
protein may also be involved in immunothrombotic events. The spike protein acts via the
MAPK/ACE2 pathway (Zhang et al., 2020). Research has suggested that vaccination against
SARS-CoV-2 can promote the downregulation of ACE2 expression (Angeli et al., 2021),
proving it to be unlikely that ACE2 is involved in thrombotic events in VITT. Thus, there is
little evidence to support the suggestion that COVID-19 disease and VITT share the same cause
of thrombosis.
When it first emerged that there were thrombotic events associated with the administration of
the adenoviral vector vaccines, vaccine administration was paused in most countries to allow
research to be conducted into the link between the vaccines and thrombosis. Although the
AstraZeneca and Janssen vaccine programmes were both continued, the level of vaccine
hesitancy associated with the adenoviral vector-based vaccines was greater than that of the
mRNA based COVID-19 vaccines (Machingaidze and Wiysonge, 2021). One point which is
stressed across numerous research publications is that although there is a risk of thrombosis
associated with vaccination, the risk of thrombosis associated with infection by SARS-CoV-2
is far greater. On infection by SARS-COV-2, thrombosis is 100 times more likely to occur in
unvaccinated patients than in those who are vaccinated (Elalamy et al., 2021).
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PATHOGENESIS OF VITT
VITT is still a relatively new condition, so there are no reports which have definitively detailed
the mechanism by which the thrombotic thrombocytopenia is caused. It is likely that VITT has
an immunological mechanism like that of HIT. There are two forms of HIT, HIT which is
induced by heparin treatment and autoimmune or spontaneous HIT, which is not caused by
heparin treatment. VITT resembles autoimmune HIT closely. PF4 and anti-PF4 antibodies play
a pathological role in both VITT and HIT (Klok et al., 2021). In HIT, anti-PF4 antibodies bind
to platelet receptor FcγRIIA, causing platelet activation and thrombocytopenia (Elalamy et al.,
2021). Activation of platelets causes the release of PF4 from platelet alpha granules. Increased
levels of PF4 can cause endothelial activation which causes the recruitment of monocytes and
neutrophils. Monocyte sidechains can then bind with PF4 to create an immune complex which
will activate monocytes, stimulating their pro-coagulant activity. This in turn leads to the
expression of tissue factor and generation of thrombin, which further stimulates the activation
of platelets (Gaunt and Mabbott, 2021). This inflammatory response also involves the
activation of neutrophils, causing a process in which foreign pathogens are trapped, called
NETosis. This process releases leukocytic DNA, which promotes the formation of
microthrombi (Elalamy et al., 2021). A similar mechanism is predicted to occur in VITT, as
depicted in Figure 1. In VITT, the binding of the anti-PF4 antibodies occurs at a different
epitope than the binding site in HIT (Huynh et al., 2021). Platelet activation is reported to occur
through CD32a, which is a platelet membrane FcγRIIA receptor (Elalamy et al., 2021).

Figure 1 – Proposed pathogenesis of VITT (Klok et al., 2021).
In addition to the spike protein, vaccine components such as the adenoviral vector itself, the
viral capsid, free DNA, vaccine impurities, EDTA and other human proteins contained within
the vaccine have all been suggested as potential triggers for the response seen in VITT (Klok
et al., 2021). It has been shown that in the case of the AstraZeneca vaccine, the viral capsid can

5

Volume 2 Issue 1

IUJHS

06/2022

bind to spaces between the hexon proteins in PF4, allowing interaction between viral
components and PF4 (Baker et al., 2021). Before the emergence of VITT it was already known
that DNA can form complexes with PF4 which can bind to antibodies found in patients with
HIT (Greinacher, Thiele, et al., 2021). VITT appears to have an immune response involvement,
which may be triggered by EDTA, or other human proteins used in the vaccine (Greinacher,
Selleng, et al., 2021).
LABORATORY CONFIRMATION OF VITT
Reports on the laboratory indicators of VITT have been consistent since the condition was
identified. Indicators include thrombocytopenia, raised D-dimer levels, and in some cases low
fibrinogen levels and prolonged PT and aPTT. Platelet counts of ≤107x109/L, D-dimer levels
of ≤142mg/L and fibrinogen levels ≤2g/L are commonly observed in VITT patients
(Greinacher, Thiele, et al., 2021). Although these results are indicative of VITT, further testing
is required for diagnosis. VITT is characterised by the presence pf anti-PF4 antibodies, so
antiPF4 ELISA is commonly used as a diagnostic test. Anti-PF4 anti bodies have also been
found outside of VITT, with 5-7% of blood donors having detectable levels of anti-PF4
antibodies (Elalamy et al., 2021). Considering this, further testing is required to confirm that
the anti-PF4 antibodies detected in the suspected VITT patient are the cause of the platelet
activation and aggregation observed (Swan et al., 2021). Functional platelet activation assays
are often used for VITT confirmation after a positive anti-PF4 ELISA result is received (Klok
et al., 2021).
Anti-PF4 ELISA is commonly used for the detection of HIT antibodies but can be used for the
detection of VITT antibodies also (Kotal et al., 2021). The principle of the ELISA assay
involves the formation of PF4 and polyvinyl sulfonate (PVS) complexes, which are
immobilised on the surface of microwells. Anti-PF4 antibodies will bind to sites on the
PF4/PVS complexes, allowing their detection. The concentration of the anti-PF4 antibodies is
reported as an optical density (Mcfarland et al., 2012). Commonly used anti-PF4 ELISA tests
include Immucor, Hyphen and Stago assays, which have reported sensitivities of 100%, 92%
and 91% respectively when used for the detection of anti-PF4 antibodies in known positive
VITT patients (Swan et al., 2021).
Following a positive anti-PF4 ELISA result, a functional platelet activation assay should be
performed. Functional platelet activation assays for VITT have been developed based on assays
which are used for HIT diagnosis, including heparin-induced platelet activation (HIPA) assays,
and serotonin release assays (SRA) (Swan et al., 2021). The HIPA assay principle involves the
detection of platelet aggregation in the presence of heparin. The assay involves the visual
assessment of platelet aggregation within the reaction mixture, and a positive result is indicated
by the change in appearance from turbid to transparent. The SRA is based on the principle that
serotonin is released by the dense granules of platelets on activation by HIT antibodies. The
SRA involves the detection and quantification of serotonin released by patient platelets in the
presence of heparin (Minet, Dogné and Mullier, 2017). The utility of functional platelet
activation assays in the diagnosis of HIT has been well researched and documented.
These assays have been modified for use in the diagnosis of VITT by replacing heparin with
PF4 in both assays (Lavin et al., 2021). PF4-induced platelet activation (PIPA) assays have
been further modified to PF4-induced flow cytometry-based platelet activation (PIFPA) tests,
which are both used for the purpose of confirmation of a VITT diagnosis (Favaloro, 2021).
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PIPA assays have been reported to detected between 95 to 100% of VITT cases, making PIPA
a sensitive indicator of the condition (Lavin et al., 2021). HIPA and PIPA assays can in some
circumstances be used for the differential diagnosis of HIT and VITT, as the HIPA assay will
return a negative result in most VITT patients and most HIT patients will receive a negative
PIPA result (Lavin et al., 2021). The modified SRA has not been reported to show the same
sensitivity as the PIPA, with some research suggesting it is only 10% sensitive when used to
detect positive VITT cases (Swan et al., 2021). Both Anti-PF4 ELISA and PIPA assays are
currently performed by reference laboratories and not offered routinely in hospital laboratories.
TREATMENT OF VITT
The treatment of VITT generally involves two approaches. The patient must be treated for
thrombocytopenia, which generally involves intravenous immunoglobulin (IVIG) to recover
the platelet count. A form of anticoagulant should also be administered, regardless of whether
thrombosis has been identified in the patient or not (Pavord et al., 2021). This will reduce the
likelihood that patients who are in the proposed ‘pre-VITT’ stage will develop thrombosis. The
choice of treatment should be determined based on the severity of the symptoms experienced
by the patient. In cases of more serious illness, further treatment such as plasma exchange
should be considered and has been shown to be beneficial (Elalamy et al., 2021).
IVIG has been widely documented as one of the most common methods of treating
thrombocytopenia in VITT patients. IVIG inhibits the binding of anit-PF4 antibodies to the
FcγRIIA receptor, which prevents platelet activation and results in a rise in platelet count
(Bourguignon et al., 2021). IVIG administration should be combined with anticoagulant
treatment, to counteract or prevent thrombosis. Given that it is recommended to avoid heparin,
direct oral anticoagulants including fondaparinux, danaparoid and argatroban are commonly
used in VITT treatment. Some patients with VITT may experience excessive bleeding due to
thrombocytopenia, so different strategies to manage thrombosis should be considered for these
patients (Klok et al., 2021). For patients who are experiencing severe thrombocytopenia or
extensive thrombosis, plasma exchange should be considered. Mortality rates in VITT patients
increases with the presence of CVST and platelet counts of under 30x109/L, but plasma
exchange in such cases is associated with a 90% survival rate, making it a very favourable
treatment option (Pavord et al., 2021). Steroids and rituximab have also been reported to be
beneficial in settings of severe VITT (Klok et al., 2021).
CONCLUSION
While considerable research has been carried out on the clinical presentation and diagnostic
markers of VITT, there is still a lack of information on some aspects of the condition, including
how the vaccine triggers the thrombotic thrombocytopenia response observed. Initial research
reports published about VITT showed considerable variation in findings. Greater consistency
is seen in more recent publications, likely due to the accumulation of data about VITT as case
numbers of the condition have risen. Guidelines on the diagnosis of VITT have changed since
the condition was first recognised, and it is advisable that a set of guidelines which are updated
regularly should be used when diagnosing VITT, such as the recommendations set up by the
UK EHP.
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Recommendations for the treatment and management of VITT have been well-documented.
Although many cases of VITT are resolved with appropriate treatment, the fatality rate for the
condition is still very significant. This may be in part due to the fast progression of the
condition, making it difficult to make a diagnosis and start treatment before a patient becomes
considerably ill. The recognition of the proposed ‘pre-VITT’ stage could improve the overall
prognosis of the condition by increasing the chances of treating the patient before they have
developed thrombosis, which is the leading cause of fatality in VITT. Further research in this
area would be of benefit for the overall management of the condition. Expanding the
availability of Anti-PF4 ELISA and PIPA assays to hospital laboratories would lessen the time
between patient presentation and confirmation of diagnosis of VITT. Age is a known factor for
the condition, but further research into whether certain cohorts of individuals are more
susceptible to developing the condition, and the mechanism by which the vaccine triggers the
immune response seen in VITT would help in the prevention of serious illness.
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